Supply of EXTAVIA interferon beta-1b (rbe) 0.25mg (8 million IU) powder for injection vial with diluent syringe by Novartis Pharmaceuticals Australia Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the supply of therapeutic goods in Australia, aiming to ensure that these goods are safe, of high quality, and properly labelled. This Act addresses the need to balance the availability of therapeutic goods with the necessity to protect public health. The Therapeutic Goods Administration, as the delegate of the Secretary of the Department of Health and Ageing, has the authority to issue consents under this Act to address specific issues or exceptions that may arise during the regulation of therapeutic goods. The policy objective of the Act is to maintain and improve the health and safety of Australians by ensuring that therapeutic goods available in the market meet the required standards. In the specific instance mentioned, the consent granted pertains to the supply of a particular batch of a medicinal product, EXTAVIA interferon beta-1b (rbe) 0.25mg, which does not conform to the labelling requirements set out in the Therapeutic Goods Order No 69. This exception is granted subject to strict conditions, including a limitation on the batch size to ensure that the exemption does not compromise the overall safety and quality standards of therapeutic goods in Australia.

Scope and Application

The Therapeutic Goods Act 1989 applies to all therapeutic goods within Australia, encompassing a broad range of products such as medicines, medical devices, blood, and tissues. This Act regulates the import, supply, manufacture, and advertising of therapeutic goods to ensure their safety, quality, and efficacy. It applies to individuals and entities involved in any aspect of the therapeutic goods supply chain, including manufacturers, importers, and distributors. The Act's jurisdictional reach extends nationally, with its provisions applicable across all states and territories of Australia. Under sections 14 and 14A, specific exemptions can be granted for certain therapeutic goods, such as in this case where Novartis Pharmaceuticals Australia Pty Ltd received consent for a non-compliant label on a specific batch of EXTAVIA interferon beta-1b, subject to strict conditions including a limit on the batch size and the requirement to supply details to the Therapeutic Goods Administration upon shipment. This demonstrates the Act's flexibility in accommodating specific circumstances while maintaining overarching standards for therapeutic goods.

Key Provisions

The Therapeutic Goods Act 1989 (the Act) provides the framework for regulating therapeutic goods in Australia. Sections 14 and 14A of the Act allow the delegate of the Secretary of the Department of Health and Ageing to grant specific consents for certain goods, which may not fully comply with certain regulatory requirements. In this instance, the delegate has consented to the supply by Novartis Pharmaceuticals Australia Pty Ltd of a specific batch of EXTAVIA interferon beta-1b (rbe) 0.25mg (8 million IU) powder for injection vial with diluent syringe (AUST R 160079), allowing it to not conform with the Therapeutic Goods Order No 69, which pertains to the general requirements for labels for medicines (section 14(a)). This consent, given under section 14(1) of the Act, is conditional and must adhere to specific stipulations to ensure public safety and regulatory compliance. The exemption applies only to one batch of a maximum of 200 units, ensuring the scope of the exemption is tightly controlled (section 15(1)). Furthermore, detailed information about this batch must be provided to the Therapeutic Goods Administration (TGA) once the goods are shipped. To maintain transparency and traceability, the outer carton of the therapeutic goods must be the approved Australian specific carton, while only the inner labels may deviate from the compliance standards (section 15(1)). Entities governed by the Act, such as Novartis Pharmaceuticals Australia Pty Ltd, must comply with all conditions imposed by the delegate of the Secretary. This includes ensuring that any non-compliant elements are clearly identified and restricted to the specified batch. The obligation to provide detailed information about the batch to the TGA is critical for regulatory oversight and public safety. Non-compliance with these conditions can lead to serious repercussions, including potential enforcement actions by the TGA. The Act stipulates various penalties for breaches of its provisions. While specific penalties for non-compliance with the conditions of this consent are not detailed in the provided extract, the Act generally empowers the courts to impose fines and other penalties for breaches. For instance, section 26 of the Act allows for substantial penalties for non-compliance with therapeutic goods regulations. These penalties can include fines up to $22,200 for individuals and significantly higher amounts for corporations, reflecting the seriousness with which the Act treats non-compliance. In more severe cases, criminal charges may be pursued, leading to imprisonment. Such measures underscore the importance of adhering to the conditions set out in the consent and the broader regulatory framework established by the Act.